Researchers Target Prolactin Receptors to Treat Lupus

A preclinical strategy rebalances receptor forms in immune cells and reduced kidney damage in mouse models.

Updated on Nov. 2, 2026 in Diabetes

Bold flat-color vector editorial illustration of clear glass cell-culture dishes with rose-tinted liquid on a pale steel laboratory bench, with a brass pipette. — Researchers at UC Riverside and City of Hope reported a preclinical lupus strategy that rebalances prolactin receptors in immune cells and reduced kidney damage in mouse models. AI Illustration. Upload story photo >

Researchers at the University of California, Riverside and City of Hope identified a new strategy for treating lupus that targets an imbalance in prolactin receptors within disease-causing immune cells. The approach reduced inflammatory molecules and harmful immune cells while preserving their normal counterparts in human cells and mouse models.

Why it matters

Lupus occurs when the immune system produces autoantibodies that attack the body's own tissues, and the findings suggest a way to address the underlying cell imbalance rather than only its symptoms. The research is preclinical, so any treatment must still pass manufacturing, quality-control and regulatory review before clinical trials.

The study, published in Experimental and Molecular Medicine, used human cells and mouse models to show that splice-modulating oligomers can shift the balance of prolactin receptor forms in lupus immune cells. Results in animal models do not yet establish whether the approach will be safe or effective in people.

The players

University of California, Riverside

A public research university in Riverside, California, whose researchers led the study identifying the new lupus treatment strategy.

City of Hope

A comprehensive cancer and biomedical research center in Southern California whose researchers co-led the lupus study.

The details

The team developed splice-modulating oligomers, short synthetic DNA sequences that interfere with how cells process receptor messenger RNA, preventing cells from producing the long prolactin receptor form. In mouse models the treatment reduced kidney damage, and the researchers are now seeking an industry partner to advance the work.

November 2, 2026: Article published about the lupus treatment strategy

Deeper Context

Prolactin receptors are produced in long and short forms, and the study shows that shifting the balance toward the short form in lupus immune cells reduced inflammation while preserving normal cells. This extends earlier efforts to modulate hormone-receptor signaling in autoimmune disease by pinpointing a specific receptor isoform as the lever.

For people with lupus, this research points toward future therapies that could address the underlying immune imbalance and possibly reduce the risk of kidney damage. No treatment is available yet, and the approach must complete preclinical testing and regulatory review before it could reach patients.

The takeaway

Targeting the balance of specific receptor forms in immune cells may offer a path beyond symptom control in lupus. Patients and families should watch for clinical research as preclinical results move toward human testing.